ScreenerHero

DERMJourney Medical Corporation Common Stock

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · journeymedicalcorp.com
7.750USD+3.47%Mkt Cap: 218.74M $P/E: —

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap218.74M $
Enterprise Value211.30M $
Revenue (TTM)68.18M $
Gross Profit40.93M $
Net Income (TTM)-11.43M $
Revenue/Share2.552 USD
Last Price7.750 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees58
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-124.83
PEG—
EV/EBITDA173.76
EV/Revenue3.10
P/S3.10
P/B6.45
EPS (TTM)-0.24
EPS (Forward)-0.06
52W Range
4.31066% of range9.555
52W High9.555 USD
52W Low4.310 USD
Profitability
Gross Margin66.17%
Oper. Margin2.46%
EBITDA Margin1.78%
Profit Margin-18.48%
ROE-35.89%
ROA-12.08%
Growth
Revenue Growth23.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.44M $
CapEx (TTM)—
FCF Margin-8.01%
FCF Yield-2.50%
Net Debt-102.00K $
Net Debt/EBITDA-0.08
Balance Sheet
Debt/Equity0.80
Current Ratio1.59
Quick Ratio1.35
Book Value/Sh1.161 USD
Cash/Share0.9090 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.75 USD
Upside (mean)+77.4%
Target Range13.00 USD – 15.00 USD
$13.00+77.4% to mean$15.00
# Analysts4
Ownership
Shares Out.22.22M
Float15.33M
Insiders31.75%
Institutions48.59%
Short Interest
Short Ratio17.9d
Short % Float18.97%
Short % Out.10.44%
Shares Short2.87M
Short (prev mo.)2.99M
Technical
SMA 506.646 (+16.6%)
SMA 2006.995 (+10.8%)
Beta1.08
S&P 52W Chg18.16%
Avg Vol (30d)205.48K
Avg Vol (10d)302.72K
Technical Indicators
RSI (14)69.2
MACD0.1462
MACD Signal0.0166
MACD Hist.+0.1296
BB Upper7.352 USD
BB Middle6.557 USD
BB Lower5.762 USD
BB Width24.26%
ATR (14)0.4472 USD
Vol Ratio (20d)1.12x